In Q1FY16, total revenues of Alembic Pharmaceuticals increased by 18% YoY to Rs 5.8 bn (our estimates Rs 5.5 bn) compared to Rs 4.9 bn in Q1FY15, due to higher export formulations sales. The Company's operating margins decreased by 210bps to 17.5% on back of lower gross margins and higher R&D cost.